Drugs / CYC065
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05817890 | Mar 2023 → Feb 2024 | — | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04017546 | Aug 2019 → Nov 2022 | acute myeloid leukemia, myelodysplastic syndrome | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03739554 | Jan 2019 → Nov 2022 | B-cell chronic lymphocytic leukemia | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02552953 | Sep 2015 → Oct 2022 | cancer | Cyclacel Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05168904 | Oct 2021 → Oct 2024 | leukemia, myelodysplastic syndrome | Cyclacel Pharmaceuticals, Inc. | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04983810 | Jul 2021 → Apr 2025 | cancer, lymphoma | Cyclacel Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02813135 | Aug 2016 → Feb 2031 expected | childhood malignant neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYC065 | “A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With...” NCT04983810 ↗ |
| Known as | fadraciclib | “Here, we provide the first disclosure of the chemical structure of fadraciclib (CYC065), a CDK inhibitor and clinical candidate designed by further optimization from the...” PMID 32645016 ↗ Jul 2020 |
| Action | Inhibit | “a Cyclin Dependent Kinase Inhibitor” NCT02552953 ↗ |
| Modality | Small molecule | “Here, we provide the first disclosure of the chemical structure of fadraciclib (CYC065), a CDK inhibitor and clinical candidate designed by further optimization from the...” PMID 32645016 ↗ Jul 2020 |
| Route | Other | “CYC065 will be administered by 4 -hour infusion every 3 weeks.” NCT02552953 ↗ |
| Target | CDK2 | “The dual CDK2/9 inhibitor fadraciclib” PMID 41838385 ↗ Mar 2026 |